Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells

PLoS One. 2017 Oct 31;12(10):e0185843. doi: 10.1371/journal.pone.0185843. eCollection 2017.

Abstract

MF59 is an oil-in-water emulsion adjuvant approved for human influenza vaccination in European Union. The mode of action of MF59 is not fully elucidated yet, but results from several years of investigation indicate that MF59 establishes an immunocompetent environment at injection site which promotes recruitment of immune cells, including antigen presenting cells (APCs), that are facilitated to engulf antigen and transport it to draining lymph node (dLN) where the antigen is accumulated. In vitro studies showed that MF59 promotes the differentiation of monocytes to dendritic cells (Mo-DCs). Since after immunization with MF59, monocytes are rapidly recruited both at the injection site and in dLN and appear to have a morphological change toward a DC-like phenotype, we asked whether MF59 could play a role in inducing differentiation of Mo-DC in vivo. To address this question we immunized mice with the auto-fluorescent protein Phycoerythrin (PE) as model antigen, in presence or absence of MF59. We measured the APC phenotype and their antigen uptake within dLNs, the antigen distribution within the dLN compartments and the humoral response to PE. In addition, using Ovalbumin as model antigen, we measured the capacity of dLN APCs to induce antigen-specific CD4 T cell proliferation. Here, we show, for the first time, that MF59 promotes differentiation of Mo-DCs within dLNs from intranodal recruited monocytes and we suggest that this differentiation could take place in the medullary compartment of the LN. In addition we show that the Mo-DC subset represents the major source of antigen-loaded and activated APCs within the dLN when immunizing with MF59. Interestingly, this finding correlates with the enhanced triggering of antigen-specific CD4 T cell response induced by LN APCs. This study therefore demonstrates that MF59 is able to promote an immunocompetent environment also directly within the dLN, offering a novel insight on the mechanism of action of vaccine adjuvants based on emulsions.

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antigens / administration & dosage*
  • Cell Differentiation / drug effects*
  • Dendritic Cells / cytology*
  • Female
  • Influenza Vaccines / administration & dosage*
  • Mice
  • Mice, Inbred C57BL
  • Monocytes / cytology*
  • Polysorbates / pharmacology*
  • Squalene / pharmacology*

Substances

  • Adjuvants, Immunologic
  • Antigens
  • Influenza Vaccines
  • MF59 oil emulsion
  • Polysorbates
  • Squalene

Grants and funding

This work was sponsored by Novartis Vaccines and Diagnostics Srl; in March 2015 the Novartis non-influenza Vaccines business was acquired by the GSK group of companies. The sponsor was involved in all stages of the study conduct and analysis. Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) provided support with grant PON01_00117, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. For participating to this study, the author HTMV has received funding from the People Programme (Marie Sklodowska-Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013/ under REA grant agreement n°317057 HOMIN-ITN. The specific roles of all authors are articulated in the "author contribution" section.